dc.contributor.author |
Shah, Hirak |
|
dc.contributor.author |
Patel, Ashish |
|
dc.contributor.author |
Parikh, Vruti |
|
dc.contributor.author |
Nagani, Afzal |
|
dc.contributor.author |
Bhimani, Bhargav |
|
dc.contributor.author |
Shah, Umang |
|
dc.contributor.author |
Bambharoliya, Tushar |
|
dc.date.accessioned |
2020-11-30T07:26:17Z |
|
dc.date.available |
2020-11-30T07:26:17Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
http://ir.paruluniversity.ac.in:8080/xmlui/handle/123456789/8179 |
|
dc.description.abstract |
Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) is a rational target in Alzheimer's Disease (AD) drug development due to its role in amyloidogenic cleavage of Amyloid Precursor Protein (APP) in generating Amyloid β (Aβ). This β-secretase cleaves not only Amyloid Precursor Protein (APP) and its homologues, but also small series of substrates including neuregulin and β subunit of voltage-gated sodium channel that play a very important role in the development and normal function of the brain. Moreover, BACE1 is modulated at the post-translational level by several factors that are associated with both physiological and pathological functions. Since the discovery of BACE1 over a decade ago, medicinal chemistry and pharmacokinetics of BACE1 small molecule inhibitors have proven challenging for the treatment of Alzheimer's disease. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
CNS Neurol Disord Drug Targets | Volume-19 | Issue-3 |
en_US |
dc.subject |
Alzheimer's disease; Amyloid Precursor Protein (APP); Amyloid β (Aβ); BACE1; palmitoylation; β-pathway. |
en_US |
dc.title |
The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease |
en_US |
dc.type |
Article |
en_US |